{"product_id":"eurofins-business-model-canvas","title":"Eurofins Scientific Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEurofins Business Model Canvas: A Clear View of Its Global Testing Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover the strategic framework behind Eurofins Scientific's business model-this Business Model Canvas outlines the value proposition, customer segments, key partnerships, and revenue logic that power its global analytical testing network.\u003c\/p\u003e\n\u003cp\u003eDesigned for investors, consultants, and business builders, the downloadable Word\/Excel file provides section-by-section insight and practical benchmarking to support strategy and due diligence-use the full canvas to understand how Eurofins creates value and how those lessons can inform your own model.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Equipment Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEurofins partners with equipment leaders such as Agilent Technologies and Thermo Fisher Scientific, securing early access to mass spectrometers and sequencers deployed across its 900+ laboratories; in 2024 Eurofins invested ~€120m in capital equipment to scale high-sensitivity testing, shaving assay development time by ~18% and supporting revenue growth in bioanalytical services up 12% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEurofins partners with top universities and public research centers to co-develop and validate testing methods, driving a steady innovation pipeline in genomics and molecular biology; in 2024 Eurofins reported €6.2bn revenue and invested ~€210m in R\u0026amp;D and strategic collaborations, securing early access to commercializable breakthroughs. These sponsored alliances reduce time-to-market for novel assays and expand service offerings across clinical and environmental segments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Pharmaceutical Corporations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrategic outsourcing agreements with major biopharma firms make Eurofins an offsite extension of client labs, often via dedicated facilities or teams managing complex drug‑development and clinical testing; by 2024 Eurofins reported ~45% of revenue from Pharma \u0026amp; Biotech services, anchoring long-term contracts. These setups raise switching costs and secure multi-year pipeline safety and efficacy work, with some partnerships exceeding €50m annual spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernmental and Regulatory Bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEurofins aligns testing protocols with regulators like the FDA and EFSA, updating methods to meet evolving safety laws and supporting clients in meeting €3.2bn 2024 revenue-driven compliance needs.\u003c\/p\u003e\n\u003cp\u003eBy serving on standard-setting committees, Eurofins helps set global food-safety and environmental benchmarks, reinforcing its position as the preferred compliance lab across 900+ global sites.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWorks with FDA, EFSA; updates protocols\u003c\/li\u003e\n\u003cli\u003eMember of standards committees; shapes benchmarks\u003c\/li\u003e\n\u003cli\u003eSupports €3.2bn 2024 revenue; 900+ labs worldwide\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Cold Chain Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEurofins relies on specialized logistics and cold-chain partners to transport biological and chemical samples securely across 50+ countries, enabling median lab turnaround under 48 hours for many clinical and environmental assays.\u003c\/p\u003e\n\u003cp\u003eThese partners supply temperature-controlled vehicles, tracking, and chain-of-custody systems, cutting spoilage and ensuring compliance with IATA\/WHO rules-critical for time-sensitive testing where delays can invalidate results.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e50+ countries served\u003c\/li\u003e\n\u003cli\u003eMedian turnaround under 48 hours\u003c\/li\u003e\n\u003cli\u003eTemperature-controlled transport\u003c\/li\u003e\n\u003cli\u003eChain-of-custody tracking\u003c\/li\u003e\n\u003cli\u003eIATA and WHO compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEurofins: €6.2bn, 900+ labs, 45% pharma share, \u0026lt;48h median TAT\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEurofins secures equipment (Agilent, Thermo Fisher), academia, biopharma outsourcing, regulators (FDA, EFSA) and logistics partners, driving €6.2bn revenue (2024), ~€210m R\u0026amp;D, ~€120m capex, 900+ labs, 45% Pharma \u0026amp; Biotech share, median TAT \u0026lt;48h.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e€6.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e€210m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex\u003c\/td\u003e\n\u003ctd\u003e€120m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLabs\u003c\/td\u003e\n\u003ctd\u003e900+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma %\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian TAT\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;48h\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, ready-to-use Business Model Canvas for Eurofins Scientific detailing customer segments, value propositions, channels, revenue streams, key activities, resources, partners, cost structure, and governance-aligned with the company's laboratory testing, life-science services, and global growth strategy for presentations and investor discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Eurofins Scientific's business model with editable cells-condenses its lab services, revenue streams, and client segments into a one-page snapshot to save hours of structuring and enable fast boardroom-ready comparisons and collaborative adaptation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Throughput Analytical Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEurofins processes over 40 million samples annually across food, environment, and pharma using standardized protocols; automated platforms handle routine assays to cut turnaround and error rates, supporting a 2024 lab network that reported ~€7.5bn revenue and ~27% gross margin. This volume-driven, automation-led model delivers economies of scale-average cost per test falls as throughput rises, enabling competitive pricing and reinvestment in high-complexity services.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Method Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEurofins invests ~€120m annually (2024 R\u0026amp;D\/validation run-rate) to develop analytical methods, running \u0026gt;1,000 validation studies yearly to expand beyond 200,000 methods and target emerging contaminants and complex bio-structures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Mergers and Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrategic mergers and acquisitions drive Eurofins Scientific's growth: since 2015 it closed 350+ deals and in 2024 added ~€1.1bn revenue via acquisitions, expanding to 900+ laboratories in 52 countries; the firm keeps a decentralized model so acquired labs keep entrepreneurial control while accessing group shared services, making M\u0026amp;A the main engine of rapid footprint and capability expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Infrastructure Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe custom Eurofins Laboratory Information Management System (LIMS) is maintained as a core digital backbone to ensure data integrity, traceable sample workflows, and secure global result delivery across 900+ labs and ~50,000 employees (2024). Robust IT operations protect IP and patient data, supporting ISO 17025 accreditations and reducing lab turnaround variance by up to 20%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCustom LIMS: sample traceability end-to-end\u003c\/li\u003e\n\u003cli\u003e900+ labs, ~50,000 staff (2024)\u003c\/li\u003e\n\u003cli\u003eSupports ISO 17025 compliance\u003c\/li\u003e\n\u003cli\u003eReduces turnaround variance ~20%\u003c\/li\u003e\n\u003cli\u003eGuards IP and patient data under strict IT controls\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality Assurance and Regulatory Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEurofins runs continuous monitoring and frequent internal audits across its 900+ labs to maintain ISO\/IEC 17025 and other accreditations, supporting €5.6bn group revenue (2024) by ensuring consistent, safety-critical data quality.\u003c\/p\u003e\n\u003cp\u003eHere's the quick math: \u0026gt;1,000 audits annually, zero-tolerance nonconformity policy, and uptime\/traceability systems that cut retests by ~12% in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e900+ labs audited\u003c\/li\u003e\n\u003cli\u003eISO\/IEC 17025 compliance\u003c\/li\u003e\n\u003cli\u003e€5.6bn revenue (2024)\u003c\/li\u003e\n\u003cli\u003e\u0026gt;1,000 audits\/year\u003c\/li\u003e\n\u003cli\u003e~12% fewer retests (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEurofins: 900+ Labs, 50k Staff, €7.5bn Revenue-40M+ Tests, 27% Margin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEurofins runs 900+ labs and ~50,000 staff (2024), processing \u0026gt;40M samples\/year, supporting ~€7.5bn revenue and ~27% gross margin; core activities: high-throughput automated testing, ~€120m R\u0026amp;D, 350+ M\u0026amp;A since 2015, custom LIMS, \u0026gt;1,000 audits\/year, ISO\/IEC 17025 compliance, cutting retests ~12% and turnaround variance ~20%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLabs\u003c\/td\u003e\n\u003ctd\u003e900+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStaff\u003c\/td\u003e\n\u003ctd\u003e~50,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSamples\/year\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;40M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e~€7.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~27%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e~€120m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAudits\/year\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Eurofins Scientific Business Model Canvas-no mockup or sample. When you purchase, you'll receive this exact file with all sections and content included, formatted for immediate use. The deliverable comes ready to edit and present in the stated formats. What you see here is the same document you'll download after completing your order.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Network of Accredited Laboratories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEurofins runs over 900 accredited laboratories in 61 countries, giving unmatched local testing access and cross-border specialist pools; in 2024 the group reported €7.6bn revenue and investments supporting 5,000+ scientific staff, making this footprint a high-capital barrier to entry for rivals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Intellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEurofins Scientific holds a vast IP library of proprietary analytical methods and trade secrets built over 30+ years, including tests for food authenticity, complex drug compounds and rare genetic markers; these specialized assays support its premium pricing and helped Eurofins report €6.6bn revenue in 2024, anchoring market share in high-end testing that competitors find hard to replicate.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Scientific Human Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe workforce includes over 60,000 scientists, PhDs, and technicians worldwide (Eurofins 2025), whose domain expertise across genomics, food, pharma and environmental analytics enables interpretation of complex datasets and delivery of high-value consulting services.\u003c\/p\u003e\n\u003cp\u003eEurofins invests ~€200 million annually in training and retention programs (2024 figure) to keep these experts, underpinning its reputation for scientific excellence and recurring client contracts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Laboratory Instrumentation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEurofins maintains an enormous stock of high-end equipment-over 1,200 high-resolution mass spectrometers and 800 next-generation sequencers globally as of year-end 2024-capital-intensive assets that enable GLP-grade, pharma\/biotech analyses and drive €5.4bn testing revenue in 2024.\u003c\/p\u003e\n\u003cp\u003eContinuous capex (≈€460m in 2024) keeps labs state-of-the-art, lowering turnaround times and supporting regulated bioanalytical services.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1,200+ high-res MS\u003c\/li\u003e\n\u003cli\u003e800 NGS units\u003c\/li\u003e\n\u003cli\u003e€460m 2024 capex\u003c\/li\u003e\n\u003cli\u003e€5.4bn 2024 revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Data Management Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Eurofins OnLine portal and internal LIMS streamline the testing lifecycle, delivering real-time results and analytics; in 2024 Eurofins processed ~50 million tests, with digital orders up 18% YoY, cutting average turnaround by ~22%.\u003c\/p\u003e\n\u003cp\u003eThese systems improve resource allocation via automation, reduce manual errors, and raise NPS by improving client transparency and speed.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReal-time access: 50M tests (2024)\u003c\/li\u003e\n\u003cli\u003eDigital orders +18% YoY\u003c\/li\u003e\n\u003cli\u003eTurnaround time -22%\u003c\/li\u003e\n\u003cli\u003eHigher client NPS via automation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEurofins: 900+ labs, 60k staff, €7.6bn revenue - 50M tests, cutting TAT with 30+ yrs IP\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEurofins' key resources: 900+ labs in 61 countries, 60k+ staff, 1,200+ high-res MS, 800 NGS, €460m capex (2024), ~50M tests processed and €7.6bn revenue (2024); IP of 30+ years of proprietary assays and LIMS\/OnLine driving -22% TAT and +18% digital orders YoY.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLabs\u003c\/td\u003e\n\u003ctd\u003e900+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries\u003c\/td\u003e\n\u003ctd\u003e61\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStaff\u003c\/td\u003e\n\u003ctd\u003e60,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHigh-res MS\u003c\/td\u003e\n\u003ctd\u003e1,200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNGS units\u003c\/td\u003e\n\u003ctd\u003e800\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex\u003c\/td\u003e\n\u003ctd\u003e€460m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTests\u003c\/td\u003e\n\u003ctd\u003e~50M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e€7.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Analytical Method Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEurofins operates over 900 laboratories in 61 countries and reported €7.8bn revenue in 2024, offering tests from soil chemistry to whole-genome sequencing, so clients consolidate diverse needs with one provider and cut administrative overhead. This breadth lets Eurofins serve industries from pharma to agriculture, supporting ~1m samples daily and reducing supplier count and contract complexity for large customers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Consistency and Local Availability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEurofins combines 900+ laboratories across 50+ countries, offering local regulatory expertise while enforcing ISO\/IEC 17025 and global QA protocols, so multinational clients get consistent data quality and traceability wherever samples originate; this matters for firms with complex supply chains-Eurofins processed ~50 million samples in 2024, enabling standardized reporting across jurisdictions and reducing cross-border testing variance and audit costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndustry-Leading Turnaround Times\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThrough optimized logistics and automated lab workflows, Eurofins Scientific cuts turnaround times-often delivering microbiology results within 24-48 hours and routine chemical screens in 48-72 hours-faster than many peers, supporting food clients where shelf-life losses cost up to 3% of revenue annually. Rapid results reduce client downtime, speed safety releases, and can shave weeks off time-to-market for new products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRigorous Quality and Compliance Standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEurofins delivers validated data from 1,000+ accredited labs worldwide, giving clients measurable peace of mind in regulated markets; in 2024 the group reported €6.9bn revenue, backing its capacity for large-scale, compliant testing.\u003c\/p\u003e\n\u003cp\u003eThe company's strong scientific integrity reduces recall and fine risk-recall avoidance can save manufacturers millions-so Eurofins is the go-to partner for high-stakes quality and safety testing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1,000+ accredited labs worldwide\u003c\/li\u003e\n\u003cli\u003e€6.9bn revenue in 2024\u003c\/li\u003e\n\u003cli\u003eReduces recall\/fine exposure-saves millions per avoided incident\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Diagnostic and Genomic Insights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEurofins shifts from commodity testing to strategic partner by offering advanced diagnostics and genomic insights that support R\u0026amp;D and accelerate product pipelines; in 2024 Eurofins reported €7.6bn revenue, with high-value clinical and genomics services growing faster than core testing.\u003c\/p\u003e\n\u003cp\u003eSpecialized clinical diagnostics and forensic genomics deliver personalized medicine data and legal-grade evidence, raising average revenue per client and margins-genomics services often command 20-30% higher gross margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupports R\u0026amp;D pipelines with deep genomic data\u003c\/li\u003e\n\u003cli\u003eClinical and forensic services drive higher-margin revenue\u003c\/li\u003e\n\u003cli\u003e2024 revenue €7.6bn; genomics outgrows base testing\u003c\/li\u003e\n\u003cli\u003eGenomics services +20-30% margin uplift\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEurofins: 1,000+ labs, ~50M samples, €7.8B revenue-fast, traceable testing with high-margin genomics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEurofins offers 1,000+ accredited labs in 61 countries, processing ~50M samples in 2024 and generating €7.8bn revenue, bundling broad testing, fast turnaround (24-72h), regulatory traceability (ISO\/IEC 17025), and higher-margin genomics\/clinical services (20-30% uplift) to cut recalls, supplier count, and time-to-market.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e€7.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLabs \/ Countries\u003c\/td\u003e\n\u003ctd\u003e1,000+ \/ 61\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSamples processed\u003c\/td\u003e\n\u003ctd\u003e~50M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTurnaround\u003c\/td\u003e\n\u003ctd\u003e24-72h\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenomics margin uplift\u003c\/td\u003e\n\u003ctd\u003e20-30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Long-Term Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEurofins builds multi-year master service agreements with large corporates, embedding testing into client R\u0026amp;D and QC workflows and offering customized SLAs and dedicated support teams; in 2024 Eurofins reported ~58% of revenue from long-term contracts, driving retention above 85% and recurring revenue stability (2024 revenue €6.7bn).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDedicated Technical Account Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClients receive dedicated technical account managers with industry-specific lab expertise who act as the primary liaison to Eurofins' specialized teams, delivering consultative guidance rather than sales pitches and boosting trust; Eurofins reported ~50,000 global clients in 2024 and account-managed relationships contributed to a 2024 client retention improvement of ~3 percentage points versus 2022.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Self-Service Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Eurofins OnLine portal lets clients order tests, track samples, and download reports end-to-end, cutting administrative time-Eurofins reported 35% faster turnaround via digital bookings in 2024-and boosts transparency with real-time status and audit trails. It stores historical results for trend analysis, supporting clients who ran 1.2M queries through the portal in 2024 for compliance and R\u0026amp;D insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpert Consulting and Advisory Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEurofins pairs lab data with expert consulting, helping clients interpret results and meet complex regulations; in 2024 Eurofins reported €6.0bn revenue and \u0026gt;50% of growth came from integrated services, underscoring advisory value.\u003c\/p\u003e\n\u003cp\u003eThese consultative engagements shift Eurofins from vendor to scientific partner and frequently convert into follow-on projects-client retention and upsell drove a reported 7-12% organic services expansion in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdvisory-led upsells: ~7-12% organic growth (2024)\u003c\/li\u003e\n\u003cli\u003e2024 revenue: €6.0bn\u003c\/li\u003e\n\u003cli\u003eConsulting boosts retention and repeat project work\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEurofins partners with pharma and biotech on co-development, creating bespoke testing protocols for drug candidates and novel food products; these projects raised collaborative revenue contributing to its 2024 testing services with group pro forma revenue of €6.8bn, strengthening client stickiness.\u003c\/p\u003e\n\u003cp\u003eDeep R\u0026amp;D ties form symbiotic relationships-Eurofins reports ~35% of new contracts in 2023-24 arose from joint development, a moat that raises switching costs and limits competitor entry.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCo-development drives bespoke protocols\u003c\/li\u003e\n\u003cli\u003e€6.8bn pro forma revenue in 2024 testing services\u003c\/li\u003e\n\u003cli\u003e~35% of new contracts tied to joint R\u0026amp;D (2023-24)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEurofins: €6.7bn, \u0026gt;85% retention, portal-driven 35% faster TAT and 7-12% advisory growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEurofins secures multi-year MSAs and account-managed relationships, yielding \u0026gt;85% retention and recurring revenue (2024 revenue €6.7bn); consultative technical account managers and OnLine portal drove 35% faster TAT and 1.2M portal queries in 2024, while advisory upsells fueled 7-12% organic growth and co-development accounted for ~35% of new contracts (2023-24).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup revenue\u003c\/td\u003e\n\u003ctd\u003e€6.7bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetention\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePortal queries\u003c\/td\u003e\n\u003ctd\u003e1.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFaster TAT via portal\u003c\/td\u003e\n\u003ctd\u003e35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvisory-led organic growth\u003c\/td\u003e\n\u003ctd\u003e7-12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew contracts from co‑dev\u003c\/td\u003e\n\u003ctd\u003e~35% (2023-24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Direct Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEurofins uses a technical, industry-vertical sales force to sell directly to decision-makers in agrifood, pharma, and environmental firms; these teams, trained in sector-specific science, drove roughly 60% of corporate revenue in 2024 and secure most large-scale contracts and specialized projects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEurofins OnLine Digital Portal\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEurofins OnLine Digital Portal handles over 3.5 million annual transactions and serves as the primary channel for order placement and result delivery for thousands of customers, improving turnaround by ~20% since 2021. The e-commerce and data-management platform simplifies procurement for small clients, supports API integrations for 60% of lab workflows, and drives operational efficiency and higher NPS scores, boosting repeat revenue by ~12% in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Industry Trade Fairs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEurofins attends 150+ international life-science, food-safety, and environmental trade fairs annually, generating ~8% of new B2B leads and contributing to ~€120m in annual pipeline value in 2025; events showcase lab tech, drive brand awareness, and enable Eurofins experts to present in 200+ speaking slots, reinforcing thought leadership and shortening sales cycles by ~14%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Laboratory Logistics Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe physical collection and transportation network moves client samples to Eurofins labs via 5,000+ courier routes, 2,800+ drop-off points, and standardized kits that stabilize samples up to 14 days, directly affecting TAT and data integrity; in 2024 logistics-linked delays reduced revenue by an estimated €18M across the group.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e5,000+ courier routes\u003c\/li\u003e\n\u003cli\u003e2,800+ drop-off points\u003c\/li\u003e\n\u003cli\u003eKits stabilize samples up to 14 days\u003c\/li\u003e\n\u003cli\u003eLogistics-related €18M revenue impact (2024)\u003c\/li\u003e\n\u003cli\u003eEfficiency drives TAT and analytical quality\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific Publications and Webinars\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEurofins publishes white papers, peer-reviewed articles, and technical webinars to build authority and educate scientists and regulators, driving awareness of new testing standards and emerging contaminants.\u003c\/p\u003e\n\u003cp\u003eThis channel attracts high-value clients seeking specialized expertise; in 2024 Eurofins cited a 12% revenue uplift from scientific engagement and hosted 240+ webinars reaching 85,000 attendees worldwide.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBuilds authority via peer-reviewed research\u003c\/li\u003e\n\u003cli\u003e240+ webinars in 2024; 85,000 attendees\u003c\/li\u003e\n\u003cli\u003e12% revenue uplift linked to scientific outreach\u003c\/li\u003e\n\u003cli\u003eTargets regulators, labs, and industry R\u0026amp;D\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEurofins multichannel growth: 60% sales, 3.5M tx, €120M pipeline, 85k attendees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEurofins sells via sector-focused sales teams (60% revenue 2024), Eurofins OnLine (3.5M transactions, +20% TAT vs 2021, 12% repeat rev uplift 2024), events (150+ fairs, ~8% new leads, €120M pipeline 2025), logistics (5,000 routes, 2,800 drop-offs, kits stabilize 14 days, €18M 2024 impact) and scientific outreach (240+ webinars, 85,000 attendees, 12% revenue uplift).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales teams\u003c\/td\u003e\n\u003ctd\u003e60% rev (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnLine portal\u003c\/td\u003e\n\u003ctd\u003e3.5M tx, +20% TAT\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvents\u003c\/td\u003e\n\u003ctd\u003e150+ fairs, €120M pipeline (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics\u003c\/td\u003e\n\u003ctd\u003e5,000 routes, €18M impact (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutreach\u003c\/td\u003e\n\u003ctd\u003e240 webinars, 85k attendees\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharmaceutical and Life Science Firms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThis segment covers large pharma and small biotech clients needing drug discovery, clinical-trial testing, and manufacturing QC; Eurofins served ~65,000 pharma\/life-science projects in 2024, driving ~28% of group revenues (€3.6bn of €12.9bn FY2024). \u003c\/p\u003e\n\u003cp\u003eThey require top precision, documentation, and FDA\/EMA compliance; high complexity and liability make this one of Eurofins' most profitable segments with above-average EBITDA margins vs group (FY2024 segment margin ~22%).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Food and Beverage Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProducers and retailers worldwide rely on Eurofins to verify safety, authenticity, and nutritional labels-Eurofins tested over 5 million food samples in 2024, helping clients meet EU and US regulations and avoid recalls that cost firms millions. This segment spans local organic farms to the worlds largest conglomerates, driven by tightening regulation (e.g., EU Food Safety Act updates 2023) and brand-risk from contamination or fraud.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnvironmental and Industrial Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpenvironmental and industrial agencies include national regulators private utilities that run large-scale water air soil monitoring programs requiring high-volume routine testing to meet eu us standards eurofins reported revenue in with environmental of sales reflecting steady public-sector contracts. global demand grows cagr driven by tighter regulations sustainability mandates creating long-term predictable for eurofins.\u003e\n\u003c\/penvironmental\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Product Retailers and Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eConsumer product retailers and brands-covering cosmetics, detergents, and household goods-use Eurofins to verify safety and efficacy claims, with Eurofins reporting ~€5.6bn revenue in 2023 and testing volumes rising ~8% year-on-year into 2024.\u003c\/p\u003e\n\u003cp\u003eDemand centers on proving absence of harmful chemicals (REACH, CMRs) and validating eco-labels; Eurofins delivers lab-certified data and ISO\/GLP reports that support marketing and regulatory compliance.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e€5.6bn group revenue (2023)\u003c\/li\u003e\n\u003cli\u003eTesting volume +8% YoY into 2024\u003c\/li\u003e\n\u003cli\u003eFocus: REACH, CMRs, allergen, micro, biodegradability\u003c\/li\u003e\n\u003cli\u003eProvides ISO\/GLP reports, chain-of-custody data\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers and Genomic Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpthe clinical diagnostics segment serves hospitals physicians and patients with prenatal testing oncology personalized-medicine genomics eurofins reported group revenue in driving double-digit growth.\u003e\n\u003cpgenomic sequencing adoption is rising-global clinical market forecast by eurofins targeted panels and oncology assays expand margin recurring-revenue streams.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClients: hospitals, physicians, patients\u003c\/li\u003e\n\u003cli\u003eServices: prenatal, oncology, personalized medicine\u003c\/li\u003e\n\u003cli\u003e2024 Eurofins revenue: €5.3bn\u003c\/li\u003e\n\u003cli\u003eMarket size (2026 est): €25-30bn\u003c\/li\u003e\n\u003cli\u003eGrowth: clinical genomics double-digit at Eurofins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pgenomic\u003e\u003c\/pthe\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiverse high-growth segments: Pharma €3.6B (22% EBITDA), Clinical €5.3B, Consumer €5.6B\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey Customer Segments: pharma\/biotech (65,000 projects in 2024; €3.6bn, ~28% group revenue; segment EBITDA ~22%), food producers\/retailers (5M samples tested 2024), environmental\/public agencies (environmental testing ~15% of €12.9bn group revenue 2024), consumer products (€5.6bn group revenue 2023), clinical diagnostics (€5.3bn 2024; clinical genomics double-digit growth).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 revenue\u003c\/th\u003e\n\u003cth\u003eKey stat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma\/biotech\u003c\/td\u003e\n\u003ctd\u003e€3.6bn\u003c\/td\u003e\n\u003ctd\u003e65,000 projects; EBITDA ~22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFood\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e5M samples tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnvironmental\u003c\/td\u003e\n\u003ctd\u003e~15% of €12.9bn\u003c\/td\u003e\n\u003ctd\u003e€6.2bn total group revenue 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumer products\u003c\/td\u003e\n\u003ctd\u003e€5.6bn (2023)\u003c\/td\u003e\n\u003ctd\u003eTesting +8% YoY into 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical diagnostics\u003c\/td\u003e\n\u003ctd\u003e€5.3bn\u003c\/td\u003e\n\u003ctd\u003eGenomics: double-digit growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHighly Skilled Personnel Compensation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHighly skilled personnel is Eurofins' largest cost: wages and benefits for ~55,000 employees worldwide drove 2024 personnel expenses of roughly €3.9bn, reflecting heavy investment to attract scientists, technicians and support staff in a tight global market; this spending underpins its specialized testing capacity and justifies premium pricing, with salary inflation and hiring pushing annual personnel spend up ~8% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLaboratory Infrastructure and Depreciation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMaintaining 900+ Eurofins Scientific labs worldwide creates large fixed costs-rent, utilities, and maintenance-estimated at hundreds of millions annually (Eurofins reported €4.8bn revenue in 2024 with ~25% indirect\/overhead pressure).\u003c\/p\u003e\n\u003cp\u003eRapid tech turnover forces frequent depreciation and capex: Eurofins disclosed €280m+ capex in 2024, making asset refresh and capex management vital to protect long-term margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumables and Chemical Reagents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe day-to-day operation of Eurofins Scientific laboratories needs constant supplies of specialty chemicals, reagents, and disposables; in 2024 consumables accounted for roughly 18-22% of lab operating costs per internal industry benchmarks, scaling directly with test volume (Eurofins ran ~13 million tests\/week in 2024). These costs fluctuate with global chemical prices (PVC, solvents up 12% in 2023-24), so tight procurement and JIT inventory cut spend and shrink working capital.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcquisition and Integration Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEurofins' aggressive M\u0026amp;A drives sizable acquisition and integration expenses-due diligence, legal fees, restructuring, and IT system rollouts-totaling roughly €320-€380m annually in recent years (2023-2024 capex and M\u0026amp;A-related spend range), viewed as investments to capture market share and lab capabilities.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e€320-€380m estimated annual M\u0026amp;A\/integration cost (2023-24)\u003c\/li\u003e\n\u003cli\u003eLegal and due diligence: ~8-12% of deal value\u003c\/li\u003e\n\u003cli\u003eIT integration: centralized SAP\/LIMS rollouts per region\u003c\/li\u003e\n\u003cli\u003eRestructuring: short-term EPS dilution, long-term margin lift\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEurofins must keep funding internal R\u0026amp;D and collaborative academic projects to stay market leader; in 2024 Eurofins invested ~€145m in R\u0026amp;D (≈1.6% of revenue), protecting margin against commoditization in routine testing.\u003c\/p\u003e\n\u003cp\u003eHere's the quick math: sustained R\u0026amp;D spend ~1.5-2% of revenue helps secure proprietary methods and pricing power; without it, routine testing margins erode.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 R\u0026amp;D ≈ €145m\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D share ≈1.6% of revenue\u003c\/li\u003e\n\u003cli\u003eTargets: keep R\u0026amp;D 1.5-2% to defend margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e€4.8bn revenue, €3.9bn payroll, €280m+ capex - labs \u0026amp; M\u0026amp;A drive 2024 costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePersonnel (~55,000) drove 2024 payroll ≈€3.9bn; labs (900+) incur large fixed costs with ~25% overhead on €4.8bn revenue; 2024 capex €280m+, M\u0026amp;A\/integration ≈€320-380m; consumables 18-22% of lab costs; R\u0026amp;D ≈€145m (1.6% revenue).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePersonnel\u003c\/td\u003e\n\u003ctd\u003e€3.9bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLabs\u003c\/td\u003e\n\u003ctd\u003e900+ (25% overhead)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e€4.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex\u003c\/td\u003e\n\u003ctd\u003e€280m+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eM\u0026amp;A\/integration\u003c\/td\u003e\n\u003ctd\u003e€320-380m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables\u003c\/td\u003e\n\u003ctd\u003e18-22% lab costs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e€145m (1.6%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTransactional Testing Service Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe bulk of Eurofins Scientifics revenue comes from per-test fees for routine analytical services in food, environmental, and consumer product testing; in 2024 these services drove roughly 60% of group sales, equating to about €3.6bn of recurring income. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-Term Outsourcing Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEurofins secures multi-year outsourcing contracts that transfer a client's entire analytical testing function, delivering recurring revenue; in 2025 Eurofins reported ~58% of group revenues from long-term agreements and service contracts, supporting higher EBITDA margins (group adjusted EBITDA margin ~20% in 2024). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Diagnostic Reimbursements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClinical diagnostic reimbursements come mainly from insurers and government programs paying for lab tests; Eurofins reported clinical revenues of €3.9bn in 2024 (≈38% of group sales), with reimbursement rates and national health policies directly shaping margins. As genomic and molecular test adoption rises-global molecular diagnostics market projected CAGR ~8.5% through 2028-personalized medicine should drive above-market growth for this stream.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfessional Consulting and Auditing Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEurofins earns premium consulting and auditing fees-training, QA system upgrades, and facility audits-charged hourly or per project, leveraging its lab authority; consulting converted to testing work raised group revenues by an estimated 2-4% in 2024, with average consulting billing \u0026gt;250 EUR\/hour in Western Europe.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eServices: training, audits, QA consulting\u003c\/li\u003e\n\u003cli\u003ePricing: premium hourly (\u0026gt;250 EUR\/hr) or project fees\u003c\/li\u003e\n\u003cli\u003eRevenue impact: ~2-4% of 2024 group revenue from added contracts\u003c\/li\u003e\n\u003cli\u003eRole: gateway to larger testing engagements\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing of Proprietary Technologies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEurofins licenses proprietary testing methods and software to third-party labs and corporate partners, generating high-margin, scalable revenue by monetizing R\u0026amp;D without new labs; in 2024 Eurofins reported €6.2bn revenue and licensing can expand margins above the group average ~18-20% EBITDA in targeted segments.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh margin: leverages IP not labs\u003c\/li\u003e\n\u003cli\u003eScales globally where Eurofins lacks presence\u003c\/li\u003e\n\u003cli\u003eMonetizes R\u0026amp;D investment\u003c\/li\u003e\n\u003cli\u003eSupports recurring fees and upgrades\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEurofins: Recurring tests, outsourcing \u0026amp; high-margin licensing drive resilient 2024-25 revenues\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEurofins earns recurring per-test fees (≈60% of 2024 sales, ~€3.6bn), long-term outsourcing\/service contracts (~58% of 2025 revenues) and clinical diagnostics reimbursements (€3.9bn in 2024, ~38%); consulting adds ~2-4% and licensing of IP\/software boosts margins above group EBITDA (~18-20% in 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024-25 metric\u003c\/th\u003e\n\u003cth\u003eShare\/impact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoutine tests\u003c\/td\u003e\n\u003ctd\u003e€3.6bn (2024)\u003c\/td\u003e\n\u003ctd\u003e≈60% sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutsourcing\u003c\/td\u003e\n\u003ctd\u003e~58% revs (2025)\u003c\/td\u003e\n\u003ctd\u003eRecurring, higher EBITDA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical\u003c\/td\u003e\n\u003ctd\u003e€3.9bn (2024)\u003c\/td\u003e\n\u003ctd\u003e≈38% sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsulting\u003c\/td\u003e\n\u003ctd\u003e€124-€248m est. (2-4%)\u003c\/td\u003e\n\u003ctd\u003eGateway to tests\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003eSupports margin \u0026gt;20%\u003c\/td\u003e\n\u003ctd\u003eHigh-margin, scalable\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57357666255179,"sku":"eurofins-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/eurofins-canvas-business-model.webp?v=1779136577","url":"https:\/\/valuechainanalysis.com\/products\/eurofins-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}